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Defining and Treating Older Adults 
with Acute Myeloid Leukemia who 
Are ineligible for intensive Therapies
Kristen Pettit and Olatoyosi Odenike*
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
Although acute myeloid leukemia (AML) is primarily a disease of older adults (age 
≥60 years), the optimal treatment for older adults remains largely undefined. Intensive 
chemotherapy is rarely beneficial for frail older adults or those with poor-risk disease, but 
criteria that define fitness and/or appropriateness for intensive chemotherapy remain to 
be standardized. Evaluation of disease-related and patient-specific factors in the context 
of clinical decision making has therefore been largely subjective. A uniform approach to 
identify those patients most likely to benefit from intensive therapies is needed. Here, we 
review currently available objective measures to define older adults with AML who are 
ineligible for intensive chemotherapy, and discuss promising investigational approaches.
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iNTRODUCTiON
Acute myeloid leukemia (AML) is primarily a disease of older adults, with a median age at diagnosis 
of 66 years in the United States (1). Age has consistently emerged as an independent prognostic risk 
factor, with the prognosis declining particularly after 60 years of age (2–5). While the overall survival 
for younger patients with AML has improved somewhat over the past few decades, the prognosis for 
older patients remains consistently dismal (6, 7).
A variety of factors have been implicated in the poor outcomes of patients with advanced age. 
Older patients are more likely to have biologically poor-risk disease than their younger counterparts, 
including a higher incidence of poor-risk karyotypic abnormalities. Within each cytogenetic risk 
category, including intermediate and favorable risk groups, outcomes are worse with advancing age 
(8–11). In addition, older adults are more likely to develop AML in the setting of an antecedent 
hematologic disorder, which also confers a worse prognosis. Most cases of AML in patients over the 
age of 60, however, arise de novo and nearly half are cytogenetically normal (CN) (12, 13). In older 
patients with CN-AML, molecular variables can be helpful in refining risk (14–16).
Abbreviations: AML, acute myeloid leukemia; CCI, Charlson comorbidity index; CN-AML, cytogenetically normal acute 
myeloid leukemia; CR, complete remission; CRi, CR with incomplete hematologic recovery; CRp, CR with incomplete platelet 
recovery; ECOG PS, eastern cooperative oncology group performance status; ELN, European LeukemiaNet; EMA, European 
Medicines Agency; FDA, United States Food and Drug Administration; FLT3, FMS-like tyrosine kinase 3; GO, gemtuzumab 
ozogamicin; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; ITD, internal tandem duplication; KPS, 
Karnofsky performance status; LDH, lactate dehydrogenase; MDS, myelodysplastic syndrome; NPM1, nucleophosmin 1; PI3K, 
phosphoinositide 3-kinase; PLK1, polo-like kinase inhibitor 1; PR, partial response; SPPB, short physical performance battery; 
WHO, World Health Organization.
TABLe 1 | Short physical performance battery.
Test instructions Scoring
Chair 
stand 
test
Have patient cross their arms across 
their chest and stand from a seated 
position without the use of their arms 
five times, as quickly as they can. 
Measure the time that this takes the 
patient
<11.19 s = 4
11.20–13.69 s = 3
13.70–16.69 s = 2
>16.7 s = 1
Unable to complete = 0
Gait 
speed 
test
Measure the time required for the 
patient to walk 4 m at a normal pace 
(best out of two attempts)
<4.82 s = 4
4.82–6.20 s = 3
6.21–8.70 s = 2
>8.70 s = 1
Unable to complete = 0
Balance tests
Side-
by-side 
stand
Have patient stand with their feet 
together for 10 s
Able to complete = 1
Unable to complete = 0 
(and do not proceed to 
semi-tandem or tandem 
stands)
Semi-
tandem 
stand
Have patient stand with their feet 
staggered for 10 s
Able to complete = 1
Unable to complete = 0 
(and do not proceed to 
tandem stand)
Tandem 
stand
Have patient stand with one foot 
directly in front of the other for as long 
as possible (up to 10 s)
10 s = 2
3–9 s = 1
<3 s = 0
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Patient-specific factors also contribute to outcomes independ-
ent of AML characteristics. For example, worse performance 
status (10, 17, 18) and the presence of comorbid conditions have 
been associated with increased mortality and decreased response 
rates in this population (19, 20).
The tendency to manage older adults with less intensive 
measures may contribute to worse outcomes. Several studies 
have demonstrated improved survival for older patients receiving 
intensive induction chemotherapy compared to those receiving 
supportive care alone (2, 21). In the United States, however, <40% 
of older adults with AML receive chemotherapy for their disease 
(3). These data suggest a need for an improved understanding 
of factors that define ineligibility for an intensive treatment 
approach.
Defining this subset of patients who are not eligible for inten-
sive therapy involves a great deal of subjectivity, and criteria have 
yet to be standardized across or within institutions. This review 
will focus on factors that should be taken into consideration 
to determine eligibility for an intensive treatment approach in 
AML and evolving treatment strategies, including investigational 
approaches, for older adults considered less fit for intensive 
induction therapy.
FACTORS THAT DeTeRMiNe eLiGiBiLiTY 
FOR iNTeNSive iNDUCTiON 
CHeMOTHeRAPY
Physical Performance
Physical performance can be used to help predict outcomes 
in older patients with AML who are treated with induction 
chemotherapy. Methods available to quantitatively assess physical 
performance include the Eastern Cooperative Oncology Group 
performance status (ECOG PS), the Karnofsky performance 
status (KPS), and the short physical performance battery (SPPB). 
Retrospective analysis of data from clinical trials of patients 
treated with an intensive induction chemotherapy approach 
showed that in patients older than 65 years with poor ECOG PS 
of 2 or 3, outcomes declined drastically with age. For example, 
among patients with an ECOG PS of 3, the likelihood of early 
death increased from 0% in those <56 years to 29% in patients 
56–65 years, and 82% in patients >75 years. However, for those 
with ECOG PS of 0–1, age appeared to have only a modest effect 
on the incidence of early death after induction chemotherapy 
(10). Another retrospective analysis of 998 patients age 65 years or 
older who underwent induction chemotherapy reported 8-week 
mortality rates of 23, 40, and 72% for patients with ECOG PS of 
0–1, 2, and 3–4, respectively. The same groups had 1-year overall 
survival rates of 35, 25, and 7%, respectively (22). Similarly, the 
KPS has been shown to help predict outcomes in older patients 
(17, 23).
The SPPB (Table 1) is another objective measure of physical 
performance and has been shown to predict future disability, 
hospitalizations, and mortality among elderly patients in general, 
with or without a malignancy. The test is relatively simple to 
perform in the clinic in only a few minutes’ time and includes 
measures of balance, gait speed, and time to rise from a chair. 
Scores range from 0 through 12, with a score of 12 representing 
the most physically fit patient. A single-center study showed an 
association between lower SPPB score and increased risk of death 
specifically in patients older than 60 years with newly diagnosed 
AML undergoing intensive induction therapy. All evaluated 
patients had a reported EGOG PS of 0–1 at the time of evalua-
tion. Those with SPPB scores <9 had a shorter median survival 
than those with scores >9 (6 versus 16.8 months, respectively). 
When analyzed as a continuous variable, each 2-point increase 
in SPPB score was associated with a 15% decrease in hazard ratio 
for death. This study showed that the SPPB is a valuable tool to 
further risk-stratify those with good ECOG PS who may have a 
lower functional reserve (20).
Comorbid Conditions
Comorbid conditions should also be taken into account when 
discussing AML management in older adults, as they portend 
worse prognoses and increased toxicity for patients undergoing 
intensive induction chemotherapy. Either the Charlson comorbid-
ity index (CCI) or the hematopoietic cell transplantation-specific 
comorbidity index (HCT-CI) can be used to measure comorbid 
conditions quantitatively. Neither of these indices was initially 
designed for use in older patients with AML, but both have been 
studied in this population with varying results.
The CCI assigns point values for certain comorbid conditions, 
some of which are stratified for severity. The original CCI has been 
revised slightly for use in older adults with AML. A single-center 
retrospective study showed that patients with a CCI score >1 had a 
significantly lower chance of attaining a complete remission (CR) 
than those with a score of 0 or 1 (35 versus 63%). The group with 
TABLe 2 | HCT-Ci (24).
Comorbidity Definition Score
Cardiac Coronary artery disease, congestive heart failure 
with ejection fraction <50%
1
Arrhythmia Atrial fibrillation, sick sinus syndrome, ventricular 
arrhythmias
1
Inflammatory 
bowel disease
Crohn’s disease or ulcerative colitis 1
Diabetes Requiring treatment (either insulin or oral 
hypoglycemic)
1
Cerebrovascular 
accident
Cerebrovascular accident or transient ischemic 
attack
1
Psychiatric Depression/anxiety requiring treatment (including 
psychotherapy)
1
Mild hepatic Chronic hepatitis, bilirubin 1–1.5 × ULN, or AST/
ALT 1–2.5 × ULN
1
Obesity Body mass index >35 kg/m2 1
Infection Documented infection or fever of unknown origin 
requiring antimicrobial treatment
1
Rheumatologic Systemic lupus erythematosus, rheumatoid arthritis, 
polymyositis, mixed connective tissue disease, 
polymyalgia rheumatic
2
Peptic ulcer Peptic ulcer disease requiring treatment 2
Moderate/
severe renal
Serum creatinine > 2 mg/dL, on dialysis, or prior 
renal transplantation
2
Moderate 
pulmonary
DLCO and/or FEV1 > 65–80%, or dyspnea on slight 
activity
2
Prior solid tumor Treated at any time in the past (excluding non-
melanomatous skin cancer)
3
Heart valve Any valvular disease (excluding mitral valve 
prolapse)
3
Severe 
pulmonary
DLCO and/or FEV1 < 65%, or dyspnea at rest, or 
requiring supplemental oxygen
3
Moderate/
severe hepatic
Cirrhosis, bilirubin > 1.5 × ULN, or AST/
ALT > 2.5 × ULN
3
ALT, alanine transaminase; AST, aspartate transaminase; DLCO, diffusing capacity of 
the lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; ULN, upper limit 
of normal.
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higher scores also showed a trend toward higher 8-week mortality 
and lower 2-year survival (19, 20).
The HCT-CI (Table 2) was developed to improve the sensitiv-
ity of the CCI in the stem cell transplant setting, but has been 
evaluated as a tool to predict outcomes with intensive induction 
chemotherapy for AML as well. A retrospective study of 177 
patients over the age of 60  years receiving induction chemo-
therapy for AML showed that HCT-CI scores of 0, 1–2, and >2 
corresponded to early death rates of 3, 11, and 29%, respectively. 
The same groups had median overall survival times of 45, 31, and 
19 weeks (24). A single-center study demonstrated that HCT-CI 
score ≥3 in older patients with AML was the single most signifi-
cant predictor of overall survival and early death, even outweigh-
ing karyotype in that study (25).
Cognitive Function
Cognitive function should not be overlooked when considering 
treatment options for older adults with AML, as pretreatment 
cognitive impairment may increase the risk of complications 
during and after intensive therapy for AML (20). Data in this area 
are limited, but a few small studies have shown that cognitive 
impairment is common in this population and is an independent 
predictor of outcome. One study with a mean age of 70.8 years 
found that 31.5% of their patients had cognitive impairment at 
the time of diagnosis of AML (17). Another study from the same 
group showed that older patients with AML receiving induction 
chemotherapy with a modified mini-mental state exam score 
of <77 out of 100 had a median overall survival of 5.2 months 
compared to 15.6 months in those with a score ≥77 (20).
Prognostic Models
Several prognostic models have been developed to risk-stratify 
and predict outcomes of patients undergoing induction chemo-
therapy based on patient and disease characteristics. An analysis 
of 2483 patients age 60 years or older enrolled in two UK trials 
showed that cytogenetic group, age, white blood cell count, per-
formance status, and type of AML (de novo or secondary) were all 
associated with outcome in patients treated with either intensive 
or non-intensive regimens. When these factors were used to 
stratify patients into good, standard, and poor-risk groups, the 
1-year survival rates were 53, 43, and 16%, respectively (26).
In a single-institution study of 998 patients age 65  years or 
older with AML treated with intensive chemotherapy, significant 
predictors of outcome were age ≥75 years, unfavorable cytoge-
netics, ECOG PS >2, antecedent hematologic disorder, lactate 
dehydrogenase (LDH) >600 IU/L, elevated creatinine, and treat-
ment outside of a laminar air flow room. They went on to devise 
a scoring system based on the number of poor prognostic factors 
present. Those with none of the above risk factors had >60% CR 
rates, induction mortality of 10% within 8 weeks of treatment, 
and 1-year survival over 50%. This favorable group accounted 
for 20% of their study population. However, those with three or 
more risk factors had CR in <20%, induction mortality of >50%, 
and 1-year survival of <10%. This high-risk group accounted for 
25–30% of their sample size (22).
Another prognostic model comes from a study of over 1400 
older patients with AML who were otherwise healthy and were 
treated on a clinical trial with standard induction chemotherapy. 
This tool uses a formula including variables such as body tempera-
ture, hemoglobin, platelet count, LDH, age, type of AML (de novo 
or secondary), fibrinogen level, and molecular and cytogenetic 
features of the disease to predict probabilities for response and 
early mortality (27).
In a study of over 900 patients over the age of 60 years with 
AML who received standard induction chemotherapy followed 
by one cycle of consolidation, independent predictors of sur-
vival included karyotype, CD34 expression, white blood cell 
count at diagnosis, age, LDH, and nucleophosmin 1 (NPM-1) 
status. Karyotype was, by far, the most significant predictor of 
survival. Those with favorable risk cytogenetics fared the best, 
regardless of other factors, with 3-year overall survival rates 
of about 40%, while those with poor-risk cytogenetics had a 
dismal 3-year overall survival of only 3%. With this in mind, 
the authors devised a prognostic score to better define the risk 
for those in the intermediate cytogenetic category. Those with 
TABLe 3 | evolving criteria for fitness in older adults with AML (30).
Risk category Patient characteristics
Frail ECOG PS ≥ 3
Impaired activities of daily living
Major comorbidity (CCI or HCT-CI > 1)
Vulnerable ECOG PS < 3 with no major comorbidity
Impaired objectively measured physical function (SPPB < 9)
Impaired cognition (modified mini-mental state score <77)
Fit Absence of all above risk factors
CCI, Charlson comorbidity index; ECOG PS, Eastern Cooperative Oncology Group 
performance status; HCT-CI, hematopoietic cell transplantation-specific comorbidity 
index; SPPB, short physical performance battery.
December 2015 | Volume 5 | Article 2804
Pettit and Odenike Managing AML in Unfit Patients
Frontiers in Oncology | www.frontiersin.org
intermediate cytogenetics and more than three points on this 
scale were grouped into a category that they called “adverse 
intermediate,” while those with similar cytogenetics but three 
points or less were coined “good intermediate.” The 3-year sur-
vival rate for those in the adverse intermediate group was only 
10.6%, as opposed to 30% for those in the good intermediate 
group (28).
At the moment, there is no consensus regarding a uniform 
set of guidelines that affirm fitness for intensive induction 
chemotherapy. The aforementioned prognostic scoring models, 
physical performance evaluation, comorbidity indices, and cog-
nitive assessments can guide decision making in a more objective 
manner. However, validated guidelines are needed to standardize 
our treatment approaches globally. Several proposed guidelines 
have arisen from expert opinion and objective data, but no one 
algorithm has emerged as the standard in patient care. One such 
guideline developed by the Italian Society of Hematology (SIE), 
Italian Society of Experimental Hematology (SIES), and Italian 
Group for Bone Marrow Transplantation (GITMO) uses age, 
performance status, and comorbid burden to define fitness for 
intensive or non-intensive therapies (29). Table 3 demonstrates 
another evolving set of criteria for fitness, vulnerability, and 
frailty based on performance status, comorbidity assessment, 
and cognitive assessment that was recently proposed based on 
review of available evidence (30). Preliminary results of a separate 
consensus guideline, based on several patient-specific criteria 
and validated in a retrospective evaluation of 362 patients diag-
nosed and treated at multiple centers, were recently presented. 
This study demonstrated that the proposed criteria were able to 
predict for overall survival, regardless of the treatment modality. 
When combined with European LeukemiaNet (ELN) risk crite-
ria (31), this model was able to identify a subgroup of fit, low/
intermediate-I risk patients who did relatively well with a median 
overall survival of 20 months. Fit patients with intermediate-II 
risk or higher fared significantly worse, with a median overall 
survival of 8.5 months (32). This underscores the fact that these 
proposed tools still require the clinician to consider the patient’s 
fitness in the context of the disease biology. Some fit older 
patients with the highest risk disease may not derive sufficient 
benefit from standard induction chemotherapy to outweigh the 
risks, and these patients may be best served by consideration of 
alternative novel therapeutic strategies. A more uniform stratifi-
cation of both fitness of the older patient for chemotherapy and 
appropriateness of that therapy in the context of disease biology 
would help inform clinical decision making as well as facilitate 
clinical trial design.
THeRAPeUTiC STRATeGieS FOR 
PATieNTS wHO ARe UNFiT FOR 
STANDARD iNDUCTiON CHeMOTHeRAPY
Treatment options for patients deemed ineligible for intensive 
induction chemotherapy are few. Possible approaches may involve 
clinical trial participation, lower-intensity chemotherapeutics 
such as DNA hypomethylating agents, or supportive measures 
alone.
DNA Hypomethylating Agents
The DNA hypomethylating agents decitabine and azacitidine are 
commonly used to treat this population. Both are approved by 
the US Food and Drug Administration (FDA) for the treatment 
of myelodysplastic syndrome (MDS). Decitabine is also approved 
by the European Medicines Agency (EMA) for AML, and azacidi-
tine is approved for AML with 20–30% bone marrow blasts that 
arose from MDS. Both drugs are generally well tolerated and can 
provide some benefit in certain older patients with AML.
Decitabine has been investigated in the frontline setting in older 
adults with AML. A phase III, multicenter study was performed 
for patients >65  years with newly diagnosed AML comparing 
decitabine administered on a 5-day schedule in 28-day cycles 
to conventional care, which consisted of either best supportive 
care or low-dose cytarabine. The decitabine cohort demonstrated 
significantly higher CR rates (17.8 versus 7.8%). There was a trend 
toward increased median overall survival (7.7 versus 5 months, 
p = 0.11) that did not reach statistical significance. After another 
year of follow-up, the survival difference between the two groups 
did reach significance (p = 0.037) (33). The EMA approved decit-
abine for older adults with AML based on these data. However, 
the FDA declined a decision that has been criticized by some as 
representative of overly stringent statistical analysis (34). A phase 
II single-institution study of 53 older patients with AML not 
eligible for intensive therapy suggested that a higher CR rate can 
be obtained when decitabine is given for 10 consecutive days as 
opposed to 5-day MDS-like regimens. In fact, an impressive 47% 
of their patients attained a CR, and an additional 17% had no 
morphologic evidence of disease but had incomplete count recov-
ery. Of those who achieved a CR, the median time to response was 
three cycles. One-year survival of even the poor-risk patients in 
this study was 30% (35). The results from this trial have led to the 
hypothesis that a 10-day schedule of administration may be more 
active for this agent in patients with AML and has led to further 
investigation of this schedule of decitabine in a recent cooperative 
group trial conducted in patients with AML >60 years of age (36).
Azacitidine has shown clinical activity in older patients with 
AML. In a phase III study (CALGB 9221) patients with MDS 
[45 had AML by current World Health Organization (WHO) 
criteria] were randomized to either azacitidine or best supportive 
care, with crossover to azacitidine permitted at the time of disease 
progression. The azacitidine arm demonstrated significantly 
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improved response rates (60% overall response in the azacitidine 
group including 7% CR versus 0% in the supportive care arm). 
The response rates were similar between patients with MDS and 
AML in a subgroup analysis. The azacitidine group also reported 
significantly better quality of life measures, including fatigue, 
dyspnea, physical functioning, and psychosocial stress (37). In a 
landmark phase III study, AZA-001, patients were randomized to 
either azacitidine daily for 7 days of a 28-day cycle or a predefined, 
investigator’s choice conventional care regimen, which included 
best supportive care, low-dose cytarabine, or intensive induction 
chemotherapy. Most of the enrolled patients had MDS, but about 
one-third met WHO criteria for AML, with 20–30% blasts. A sur-
vival advantage was demonstrated for the azacitidine arm of the 
trial overall including the subgroup with WHO-defined AML. In 
that subgroup, median overall survival in the azacitidine arm was 
24.5 versus 16 months in the conventional care regimen arm (38).
Preliminary results of the AZA-AML-001 study were recently 
presented. This phase III, multi-institution study compared 
azacitidine to conventional care regimens including intensive 
induction chemotherapy, low-dose cytarabine, or best supportive 
care in patients ≥65 years with AML and blast count >30%. The 
primary endpoint of median overall survival was 10.4 months in 
the azacitidine arm versus 6.5 months in the conventional care arm, 
which did not quite achieve statistical significance (p = 0.0829). 
There was a trend toward an improvement in the 1-year overall 
survival rates in the azacitidine arm as well (47 versus 34%) (39).
Emerging data suggest that certain subsets of patients may 
be more likely to respond to hypomethylating therapy. In an 
updated subgroup analysis of the AZA-AML-001 study, patients 
with morphologic dysplastic changes treated with azacitidine 
had twice the median overall survival than their morphologically 
similar counterparts treated with a conventional care regimen 
(12.7 versus 6.3 months, p = 0.0357) (40). There was some initial 
evidence that hypomethylating agents may be more effective in 
AML characterized by DNMT3A mutations; however, follow up 
studies were conflicting (41, 42). Recent reports also demon-
strated that patients with TET2 mutations are more sensitive to 
treatment with hypomethylating agents (43, 44). Further studies 
examining biological factors predicting response to epigenetic 
therapies are necessary and are ongoing.
Low-Dose Cytarabine
Low-dose cytarabine represents another available option outside 
of a clinical trial for patients unfit for intensive therapy and 
remains a frequently used comparator or combination partner 
in clinical studies in this patient population (45). In a multicenter 
phase III trial, 217 patients with AML or high-risk MDS deemed 
unfit for intensive therapy were randomized to receive either low-
dose cytarabine 20 mg twice daily for 10 days or hydroxyurea. 
The low-dose cytarabine group had a higher CR rate (18 versus 
1%) and improved overall survival with an odds ratio of 0.60.
Gemtuzumab Ozogamicin
In recent years, there has been a concerted effort to develop 
novel agents with better efficacy and toxicity profiles particu-
larly for those patients who are considered unfit for standard 
induction approaches. Gemtuzumab ozogamicin (GO) is 
an antibody-drug conjugate that consists of an anti-CD33 
antibody linked to calicheamicin. GO was granted accelerated 
FDA approval for patients with CD33+ AML in first relapse 
who were not candidates for cytotoxic chemotherapy based on 
several open-label studies showing improved outcomes in this 
population (46–48). However, the confirmatory SWOG 106 
study, which involved the addition of GO to standard induc-
tion therapy in a separate population, namely untreated adults 
≤60  years old, found an increase in 30-day mortality in this 
population which prompted the voluntary withdrawal of GO 
from the market, and thus it is no longer routinely available to 
older patients with AML (49).
Several subsequent studies focusing on older patients with 
AML have shown improved outcomes when GO is added to con-
ventional therapy. In one randomized study comparing induction 
chemotherapy alone versus induction chemotherapy plus GO in 
older patients ranging from 51 to 84 years old with AML, there 
was no difference in response rates, early mortality, or toxicities 
between the two groups, but at 3-year follow up, there was a 
decreased relapse rate (68 versus 76%, p = 0.007) and improved 
survival (25 versus 20%, p = 0.05) in the group who received GO 
(50). Another trial randomized 495 older patients with AML 
ranging from 54 to 90 years old who were deemed inappropriate 
candidates for intensive therapy to low-dose cytarabine with or 
without GO. The addition of GO resulted in significantly improved 
remission rates (30 versus 17%, p = 0.006), but no improvement 
in mortality at 12 months (51).
The role of GO as post-remission therapy for older patients has 
also been investigated. A phase III multicenter study randomized 
patients over the age of 60 years in remission after intensive therapy 
to receive either three cycles of GO or no post-remission therapy. 
They found no difference in relapse rates, disease-free survival, 
or overall survival (52). The ultimate fate of this agent has yet to 
be determined, but many experts have vocally advocated for its 
reinstatement in our treatment armamentarium (53–55).
NOveL AGeNTS UNDeR iNveSTiGATiON
In recent years, there has been an increasing focus on molecularly 
targeted therapies in oncology, and AML is no exception. Several 
targeted small molecule inhibitors are under investigation for 
older patients with AML who are not fit for standard induction 
therapy. In general, these agents are hypothesized to be less toxic 
than traditional chemotherapy, and as such could be useful in 
specific molecular subsets of AML in less fit older adults either as 
single agents or in rationally designed combinations in the near 
future (Table 4).
Agents That Target the Microenvironment/
Leukemia Stem Cell
PF-04449913 is an oral agent designed to inhibit the hedgehog 
signaling pathway, which has been shown to be aberrantly 
activated in AML cells. It is currently undergoing phase I/
II trials in combination with induction chemotherapy in fit 
patients, and with either low-dose cytarabine or decitabine in 
unfit patients (56).
TABLe 4 | Selected list of investigational agents.
Agent Mechanism of action Phase of investigation ClinicalTrials.gov identifier Reference
Drugs that target the microenvironment or leukemic stem cell
PF-04449913 Hedgehog inhibitor I/II NCT01546038 (56)
Kinase inhibitors
Volasertib PLK1 inhibitor III NCT01721876 (57, 58)
GSK2141795 + trametinib RAS activation pathway inhibitor II NCT01907815 (59)
Quizartinib FLT3 inhibitor I/II NCT01892371 (60, 61)
ASP2215 FLT3/AXL inhibitor I NCT02014558 (62)
Pevonedistat NAE inhibitor I NCT01814826 (63, 64)
epigenetic therapies
Pracinostat HDAC inhibitor II NCT01912274 (65)
Valproic acid HDAC inhibitor II NCT00867672 (66, 67)
NCT00414310
Vosaroxin Topoisomerase II inhibitor I/II NCT01893320 (68)
Bortezomib NF-kB pathway inhibitor II NCT01420926 (36)
AG-120 IDH1 I NCT02074839 (69)
AG-221 IDH2 I NCT01915498 (70)
EPZ-5676 DOT1L I NCT02141828 (71)
SGI-110 DNA hypomethylator I–II NCT01261312 (72)
Others
Selinexor SINE II NCT02088541 (73)
SINE, selective inhibitor of nuclear export.
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Agents That Target Dysregulated Kinases 
or Signaling Pathways
Quizartinib, an FMS-like tyrosine kinase 3 (FLT3) receptor tyros-
ine kinase inhibitor, has shown promising results in patients with 
relapsed refractory AML, particularly those patients harboring 
an FLT3-internal tandem duplication (ITD). In a phase I study, 
responses [including CR, CR with incomplete platelet recovery 
(CRp), CR with incomplete hematologic recovery (CRi) (74), 
and partial remission (PR)] were seen in 30% of all patients 
and 53% of FLT3-ITD-positive patients treated with quizartinib 
(75). Preliminary results of a phase II trial of patients ≥18 years 
old with relapsed or refractory AML showed an encouraging 
composite CR rates (CR +  CRp +  CRi) of 44%, with nearly 
one-third of patients successfully bridged to stem cell transplant 
(60). Phase I/II studies combining quizartinib with azacitidine 
or low-dose cytarabine are ongoing (61). Quizartinib is an oral 
agent and has been generally well tolerated, making it an exciting 
prospect for less fit patients with AML. Another multi-targeted 
tyrosine kinase inhibitor, ASP2215, is also in ongoing phase I 
trials (62).
Volasertib, a small molecule inhibitor of the polo-like kinase 
1 (PLK1) protein, was combined with low-dose cytarabine and 
compared to low-dose cytarabine alone in a randomized, phase 
II trial for unfit patients with AML. The combination arm showed 
improved CR + CRi (31 versus 13.3%, p = 0.052) (57). The phase 
III trial is ongoing (58).
GSK2141795, a novel agent that blocks the phosphoinositide 
3-kinase (PI3K)/AKT signaling pathway, is being studied in a 
phase II trial of unfit patients with RAS-mutated AML in combi-
nation with the MEK inhibitor trametinib (59).
Studies with Pevonedistat, a first-in-class inhibitor of NEDD-8 
activating enzymes (NAE) in combination with azacitidine are 
ongoing. In phase I, this combination was safe and generally well 
tolerated. Among the 18 patients evaluable for response, a 56% 
ORR was reported (63). Phase II is underway.
epigenetic Therapies
Besides the DNA hypomethylating agents discussed above, 
other epigenetic therapies such as histone deacetylase inhibi-
tors are also of interest in this population, and combination 
approaches are being evaluated (76). Phase II studies combin-
ing pracinostat with azacitidine in older adults with AML are 
accruing (65), and preliminary results are encouraging (77). 
The role of valproic acid, perhaps in combination with all-trans 
retinoic acid and other epigenetic modifiers, has yet to be fully 
elucidated (66). Other combinations of epigenetic therapy with 
different modalities continue to be studied. Examples include 
the topoisomerase-II inhibitor vosaroxin plus decitabine (68, 
78) and bortezomib plus decitabine (79). Mutations in IDH1 
and IDH2, which inhibit TET2 enzymatic function and thereby 
result in DNA hypermethylation, also represent novel epige-
netic targets. Phase I studies of oral IDH1 and 2 inhibitors in 
patients with the respective mutations are ongoing (69, 70). 
DOT1L, a histone methyltransferase that plays a critical role 
in leukemic transformation induced by MLL rearrangements, 
is also a promising therapeutic target that is being investigated 
in early phase trials in MLL-rearranged leukemias (71, 80). 
Novel analogs and/or novel formulations of existing DNA 
methyltransferase inhibitors are also under active investigation 
in AML (72).
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Other Novel Agents
Selinexor, an oral selective inhibitor of nuclear export (SINE), is 
currently being investigated in a phase II randomized trial for 
unfit patients as a single agent versus physician’s choice, which 
includes hypomethylating agent or supportive care (73). There 
are also ongoing early phase trials investigating this agent in com-
bination with chemotherapy or hypomethylating agent therapy.
Of course, the importance of supportive measures for patients 
undergoing less intensive therapy or no therapy should not be 
overlooked. Prophylactic antimicrobials, transfusion of blood 
products as needed, and hydroxyurea if needed for cytoreduc-
tion can all be utilized in an effort to reduce hospitalization 
rates in older patients with AML with the hope of improving 
quality of life.
CONCLUSiON
As the world’s population continues to age, the number of people 
diagnosed with AML each year can be expected to rise, adding 
urgency to the need for more effective and less toxic therapies for 
older, less fit adults. Available therapies outside of the realm of 
clinical trials are few. Clinical trial participation should be con-
sidered the standard of care for unfit patients and patients with 
high-risk disease whenever possible. Developing and validating 
uniform definitions for risk stratification according to fitness 
and integrating this within the context of disease biology are of 
utmost importance with regard to the design, implementation, 
and interpretation of clinical trial data in this patient population.
The criteria that define patients unfit for intensive induction 
chemotherapy are currently evolving and require validation. 
Therefore, at the present time, we recommend that clinicians 
incorporate the currently available tools described herein plus 
patient preferences in the development of treatment strategies 
for the individual patient.
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